BOUCHERVILLE, QC / ACCESSWIRE / July 2, 2015 / Orimed Pharma announced today the availability of Zestra(R) and Uxor(TM) (sold in the US as EjectDelay(R)) for the Canadian market the summer of 2015.
The pre-launch activities included a strongly formed clinical advisory day that was attended by 17 Canadian doctors and opinion leaders in sexual dysfunction, as well as by both company's executives. It took place in Montreal and was followed by strong press and media exposures. Orimed Pharma is launching with over 225,000 doses of the products.
Zestra will be available in two formats, 3-packets and 12mL multi dose bottle. The 3-packet box will be priced around $13,50CDN at the pharmacy level and the multi dose bottle will be price under $40CDN.
Uxor will be available in a 2 oz tube and will be priced under $18CDN.
Both products will be available behind the counter as opposed to over the counter as it is sold in the US.
"Orimed is proud to be among the first healthcare companies to not only recognize the credible medical need presented by common sexual dysfunctions like FSIAD and premature ejaculation, but to also make clinically proven and approved solutions accessible to the patients in Canada," said Bernard Fortier, Director of Orimed Pharma Inc.
About Zestra(R)
Zestra(R), licensed from Innovus Pharmaceuticals (OTCQB: INNV) is a hormone-free medicated topical treatment that improves the local neurosensitivity and increases vasodilation, will be available behind the counter at pharmacies beginning June 2015. Two clinical trials published in the Journal of Sex & Marital Therapy established that Zestra(R) significantly improves a woman's desire, arousal and sexual satisfaction: 70% of women reported improved sexual satisfaction over multiple uses of the product.
About FSIAD
Female Sexual Interest and Arousal Disorder (FSIAD), a disorder classified in the DSM-5 that is characterized by a lack of sexual interest or arousal and is estimated to affect as many as 4 in 10 women, with the highest prevalence occurring in those between 45 and 64 years of age(2). The condition comes with both physical and emotional consequences: women with FSIAD can experience persistent depression and difficulties with their relationships.
About Uxor(TM)
UXOR(TM), also licensed from Innovus Pharma and sold under the tradename Ejectdelay(R) in the US, is a mild local anesthetic containing a proprietary formulation of benzocaine and approved by Health Canada to treat premature ejaculation, will be available at pharmacies across Canada at the beginning of August 2015.
About Premature Ejaculation
Premature ejaculation which the International Society for Sexual Medicine defines as less than one minute of Intra-Vaginal Ejaculation Latency Time (I-ELT). Studies show that between adolescence and age 59, approximately 30% of men reported having experienced PE during the previous 12 months(3).
For more information visit:
sexforhealth.ca
zestra.ca
uxor.ca
About Orimed
Constantly driven forward by innovation, Orimed develops targeted products. Orimed focuses its efforts in finding solutions that meet physicians' and their patients' needs. Orimed is a privatelyowned Canadian pharmaceutical company.
(1): Source: A survey of 1531 Canadians was completed online between April 6 and 9, 2015 using Leger's online panel, LegerWeb. A probability sample of the same size would yield a margin of error of +/- 2.5%, 19 times out of 20.
(2): Source: SexualityandU.ca, SexualDysfunction : http://www.sexualityandu.ca/en/health-care-professionals/sexual-dysfunction
(3): Source: Laumann, E.O. et al. (1999). "Sexual Dysfunction in the United States: Prevalence and Predictors." Journal of the American Medical Association281 (6): 537–44. doi:10.1001/jama.281.6.537. PMID 10022110.
For more information:
Maxime-Elisabeth Illick
NATIONAL Public Relations
meillick@national.ca
Phone: 514-843-2322
SOURCE: Innovus Pharmaceuticals
